Completed PHASE3 INTERVENTIONAL 1-arm NCT01668914

Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Positive (IMSLNB-CANP)

Phase III Trail of Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Positive

Sponsor: Shandong Cancer Hospital and Institute

Conditions Breast Cancer

Interventions 99mTc-SC Histologic Examination IM-SLNB LSG Methylthioninium

Updated 6 times since 2017 Last updated: Apr 3, 2018 Started: Feb 28, 2014 Primary completion: Sep 30, 2017 Completion: Dec 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01668914, this PHASE3 trial focuses on Breast Cancer and remains completed. Sponsored by Shandong Cancer Hospital and Institute, it has been updated 6 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
May 2018 — Jun 2018 [monthly]

Completed PHASE3

Status: Unknown Status → Completed · Phase: PHASE2 → PHASE3

▶ Show 1 earlier version

Jan 2017 — May 2018 [monthly]

Unknown Status PHASE2

First recorded

Feb 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shandong Cancer Hospital and Institute

Data source: Shandong Cancer Hospital and Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jinan, China